Introduction {#Sec1}
============

Acute bronchitis is a respiratory tract infection limited to large airways of the lung in the absence of chronic lung disease affecting people of all ages and it is one of the most frequent medical conditions seen in ambulatory care. Clinically, acute bronchitis is characterized by cough with or without sputum production lasting 1 to 3 weeks \[[@CR1]--[@CR3]\].

The two most important meta-analyses that evaluated the use of antibiotics in acute bronchitis have not proven a clear benefit of these drugs; however, a weakness of these studies was the pooled of trials evaluating different type or combination of antibiotics. Despite it, a modest benefit in the use of antibiotics in certain subgroups of patients was described \[[@CR4], [@CR5]\].

Regardless of the current trend to decrease the use of antibiotics in this pathology, the combination of sulfamethoxazole, trimethoprim and guaifenesin (STG) is frequently used in the routine practice in Peru to treat acute respiratory tract infections, including acute bronchitis, similarly to other countries where antibiotics are used into treat these conditions \[[@CR6]--[@CR8]\].

Although the STG combination is widespread used in the routine, there is a lack of data about the safety of this combination. For this reason, we designed an exploratory trial to estimate a frequency of adverse events (AEs) associated with the treatment with STG that in order to estimate of a robust sample size for future studies evaluating the safety of this combination.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Study design {#Sec4}

This is a prospective, observational, multicenter, pilot study in pediatric and adult patients with acute bronchitis intended to explore the safety of the STG combination.

### Patients {#Sec5}

This study included patients with acute bronchitis in which the treating physician has decided to initiate treatment with the combination of STG. We describe in this report results of two cohorts of patients (adult and pediatric). Eligibility criteria for both cohorts are described in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

### Treatment schedule {#Sec6}

Administration of STG was done following physicians' recommendation according to local clinical practice and local protocols.

### Evaluations {#Sec7}

The security assessment criteria were registered. The primary variable was number of adverse events related to the STG combination (as assessed by the investigator according to the NCI-CTCAE). Study variables also included, change in dosage, change in frequency, clinical parameters affecting the safety of the combination, discontinuation of the dose, dose reintroduction, and compliance with local recommendations. The safety assessment criteria were evaluated in the final visit.

### Statistical considerations {#Sec8}

We present descriptive statistics, mean and standard deviation (SD) for quantitative data and frequencies for qualitative variables. This study planned evaluate variables associated to AEs; however, due to few number of events with definite/possible causality, it analysis was not conducted.
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                \begin{document}$$ {\rm N} = \ln ( 1- \pi) / \ln ( 1- \lambda ) $$\end{document}$$where ln = natural logarithm, π = confidence level and λ = probability of event.

To make the calculation, the following considerations were proposed: π = 0.95 (95%) and λ = 0.06 (6%). The result of the calculation is 48.4 patients. The premise of a probability adverse-drug reaction of 6% was obtained in a previous article by Nguyen et al. \[[@CR9]\], describing an adverse drug reaction rate of 9% in a cohort of patients treated with high and standard doses of the combination of sulfamethoxazole and trimethoprim where the frequency of adverse reactions for standard dose was 5.1%.

Results {#Sec9}
-------

### Characteristic of patients {#Sec10}

In total, 51 pediatric patients and 52 adult patients were included in every cohort, where 49% (n = 25) and 61.5% (n = 32) were female patients. The mean age was 7.6 years (SD ± 3.2) in pediatric patients and 42.8 years (SD ± 16.1) in adult patients. In regard to the body mass index (BMI), 39.2% of pediatric patients and 59.5% were over weighted/obese. Symptoms observed with more frequency in the pediatric cohort were cough (n = 51, 100%), fever (n = 32, 63%) and coryza (n = 51%); while most frequent symptoms in the adult cohort were cough (n = 51, 98.1%), dyspnea (n = 32, 61.5%), fever (n = 29, 55.8%), coryza and dysphonia (both in 48.1%) (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of both pediatric and adult patientsCharacteristicsPediatric patientsAdult patientsn%n%*Gender*Female25493261.5Male26512038.5*Age*Mean (years) ± SD7.6 ± 3.242.8 ± 16.1*Weight*Mean (years) ± SD29.9 ± 1368.9 ± 14.4*Height*Mean (years) ± SD1.3 ± 0.171.6 ± 0.08*BMI*Low weight1211.9Normal3058.82038.5Overweight917.62140.4Obesity1121.61019.1*Symptoms*Cough511005198.1Fever32632955.8Coryza26512548.1Dysphonia9182548.1Dyspnea8163261.5Chest wall retraction2423.8Other symptoms27531630.8

### Features of treatment {#Sec11}

In pediatric patients, duration of treatment was \< 5 days in one case, 5 days in 13.7% (n = 7); between 6 and 7 days, in 82.4% (n = 42) and \> 7 days in one case. In the adult group of patients, duration of treatment was \< 5 days in 32.7% of patients (n = 17), 5 days in 69.2% (n = 27) and between 6 and 7 days in 28.8% (N = 8) (Table [2](#Tab2){ref-type="table"}). At the last follow-up visit, 98% of pediatric patients (n = 50) and 98.1% of adult patients (n = 51) completed their treatment at their last follow-up. In total, 80.4% (n = 41) and 65.4% (38%) of pediatric and adult patients received concomitant medications, respectively. In all cases treatment was carried out under local labeling.Table 2Treatment characteristics of both cohortsCharacteristicsPediatric patientsAdult patientsn%n%*Treatment days*\< 5121732.75713.72769.26--74282.4828.8\> 7120\_*Completed treatment* ^a^Yes50985198.1No1211.9*Interruption of treatment*Yes1223.8ReasonAdverse event1100150Improvement of condition_150*Concomitant medication*Yes4180.43865.4No1019.61834.6^a^Treatment completed at the last follow up (day 10th)

### Adverse events {#Sec12}

AEs were present in 9.6% (n = 5) of pediatric and 19.2% (n = 10) of adult patients. Regarding the causality, AEs assigned as definite causality were present in 2 adult patients (gastritis and gastric discomfort); possible, in 4 pediatric (diarrhea) and 2 adult patients (nausea and vomiting and pyrosis); probable, in adult patients (headache, diarrhea, gastritis and nocturia); unlikely, in 1 pediatric (prurigo) and 2 adult patients (xerostomy and insomnia). AEs features are presented in Table [3](#Tab3){ref-type="table"}. Interruption of treatment due to AEs was observed in one pediatric and one adult patient. In none case was observed change of dose, change of frequency or treatment reintroduction.Table 3Adverse events in both pediatric and adult patientsCharacteristicsPediatric patientsAdult patientsn%n%*Adverse events*Yes59.61019.2No4688.44280.8*Causality*Definite0_220Possible480220Probable0_440Unlikely120220None0_0\_*Outcome of adverse event*Total recovery480770Recovering^a^120220Recovery with sequelae0_0\_Without recovery^a^0_110Fatal0_0\_^a^Assessed at the last day of follow-up (day 10th)

Discussion {#Sec13}
----------

Although, the most commonly etiology of acute bronchitis is viral infections, a community study conducted by Macfarlane et al. \[[@CR10]\], found 25% of cases with a bacterial infection cause, with *Streptococcus pneumoniae*, *Haemophilus influenza*, *Moraxella catarrhalis*, as the most frequent pathogens. In this, the combination of sulfamethoxazole and trimethoprim is used in the clinical setting to cover the infections \[[@CR11]\]. In the other hand, guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric patients and could improve treatment outcomes adding symptoms relief in the management of chronic bronchitis and upper respiratory tract infections and in patients-reported outcomes for acute respiratory tract infection symptoms \[[@CR12], [@CR13]\].

The use of antibiotics to treat acute bronchitis is controversial but common. In a recent study in Italy, 73.5% of events of acute bronchitis had antibiotic treatment where fluoroquinolones were the most used antibiotics by general practitioners \[[@CR14]\]. In regard to pediatric patients, the analysis of a large cohort involving 14,683 episodes of acute bronchitis, described that antibiotics were prescribed in 49.7% of cases \[[@CR15]\].

In this study of observational design in the context of routine setting in seven healthcare centers in Peru, we evaluated the safety of the combination of STG in both, pediatric and adult patients. In this work, we present the first report of the safety of the combination of sulfamethoxazole, trimethoprim and guaifenesin.

Up to date, there is scarce information in the medical literature about the therapeutic combination evaluated in this study while systematic reviews and meta-analysis evaluated pool of antibiotics rather specific interventions \[[@CR1]\]. The first Cochrane meta-analysis evaluating antibiotics in acute bronchitis were published in 2014, describing modest benefit to some group of patients \[[@CR4]\]. An update of this meta-analysis published 3 years later, do not included additional studies and had similar conclusions than the previous report \[[@CR4]\].

In our study, the pattern of treatment vary between adult and pediatric patients, where adults had longer treatments and where less likely to receive concomitant medication, although a similar rate of patients with completed treatment were observed.

On the other hand, we found the double rate of adverse events in adults in contrast to pediatric patients (≈ 10% vs ≈ 20%); however, it could be explained for a higher description of adverse events less likely to be related with the study drugs. Diarrhea was most frequent in pediatric patients while adult patients had a higher frequency of gastritis.

In this exploratory study, rates of adverse event was higher than reported previously to the combination of sulfamethoxazole and trimethoprim \[[@CR9]\]; however, these results should be taken carefully interpreted because this work is only designed to obtain a sample size for a further study.

In conclusion, the combination of STG has a good toxicity profile we report that different statistical considerations should be taken to calculate adequate sample sizes to evaluate the safety of the combination of sulfamethoxazole plus trimethoprim plus guaifenesin in adults or pediatric patients.

Limitations {#Sec14}
===========

This study had a small sample size to draw conclusions about associations between basal characteristics and the likelihood to develop AEs.The follow-up period was short (10 days) and it difficult the monitoring of adverse events.

Additional file
===============

 {#Sec15}

**Additional file 1: Table S1.** Eligibility criteria. Description of inclusion and exclusion criteria in paediatric and adult patients enrolled in this study.
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